{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:53:40Z","timestamp":1788612820358,"version":"build-2803163510"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC #10\/2021"],"award-info":[{"award-number":["FFC #10\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#06\/2021"],"award-info":[{"award-number":["FFC#06\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,11,4]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The triple cystic fibrosis transmembrane conductance regulator (CFTR) modulators combination elexacaftor\/tezacaftor\/ivacaftor (ETI) has been approved for people with cystic fibrosis (pwCF) bearing at least one\n                      <jats:italic>F508del<\/jats:italic>\n                      allele. Despite the development of CFTR modulators having dramatically improved respiratory outcomes in pwCF, clinical studies have showed variable responses to this drug formulation. Of note, airway inflammation and bacterial colonisation persist in the upper and lower respiratory tract even in ETI-treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We first tested the clinical exoproducts (EXO) of\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      isolated from 15 CF patients in wild-type (WT) and F508del-CFTR CF bronchial epithelial (CFBE) cells. We were then prompted to evaluate the effects of EXO in\n                      <jats:italic>ex-vivo<\/jats:italic>\n                      patient-derived tissues. Therefore, we cultured primary nasal epithelial cells (HNECs) with EXO isolated from the corresponding pwCF to mimic the native status of CF airway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that EXO variably decreased WT-, F508del- and ETI-dependent F508del-CFTR function and increased proinflammatory cytokines and reactive oxygen species (ROS) levels in a clinical strain-specific manner. Similarly, we observed a variable reduction of F508del-CFTR function in presence or absence of ETI and upregulation of proinflammatory cytokines and ROS levels. Interestingly, HNECs treated with EXO isolated from the corresponding donor and three different pwCF showed a variable reduction of ETI-dependent F508del-CFTR function mainly due to clinical strains with limited effect of patient background. Furthermore, we demonstrated that ETI pretreatment decreased the cytokines and ROS levels down to the levels of uninfected cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      These preclinical studies suggest that\n                      <jats:italic>in vitro<\/jats:italic>\n                      screening of patient-specific response to CFTR modulators under infection\/inflammation conditions could prove to be a valuable tool to enhance the prediction of clinical response.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00970-2024","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T10:45:20Z","timestamp":1731581120000},"page":"00970-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Deleterious effect of\n                    <i>Pseudomonas aeruginosa<\/i>\n                    on F508del-CFTR rescued by elexacaftor\/tezacaftor\/ivacaftor is clinical strain-dependent in patient-derived nasal cells"],"prefix":"10.1183","volume":"11","author":[{"given":"Caterina","family":"Allegretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"Montemitro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Noemi","family":"Sgobba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Capurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Ciciriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3557-1439","authenticated-orcid":false,"given":"Gianfranco","family":"La Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rossitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Tuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarini N.A.","family":"Gunawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onofrio","family":"Laselva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2025121505100581000_11.3.00970-2024.1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2016.1177460"},{"key":"2025121505100581000_11.3.00970-2024.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025121505100581000_11.3.00970-2024.3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807120"},{"key":"2025121505100581000_11.3.00970-2024.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2025121505100581000_11.3.00970-2024.5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.202406-1128RL","article-title":"Elexacaftor\/tezacaftor\/ivacaftor markedly reduces aspergillus fumigatus in cystic fibrosis","volume":"210","author":"Morgan","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121505100581000_11.3.00970-2024.6","doi-asserted-by":"publisher","DOI":"10.1002\/PPUL.26261"},{"key":"2025121505100581000_11.3.00970-2024.7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fcimb.2017.00470","article-title":"Quorum sensing down-regulation counteracts the negative impact of Pseudomonas aeruginosa on CFTR channel expression, function and rescue in human airway epithelial cells","volume":"7","author":"Maille","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2025121505100581000_11.3.00970-2024.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.03.010"},{"key":"2025121505100581000_11.3.00970-2024.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00076214"},{"key":"2025121505100581000_11.3.00970-2024.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127742"},{"key":"2025121505100581000_11.3.00970-2024.11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/biom10020334","article-title":"Anti-infectives restore ORKAMBI((R)) rescue of F508del-CFTR function in human bronchial epithelial cells infected with clinical strains of P. aeruginosa","volume":"10","author":"Laselva","year":"2020","journal-title":"Biomolecules"},{"key":"2025121505100581000_11.3.00970-2024.12","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/cells10082132","article-title":"Anti-inflammatory and anti-oxidant effect of dimethyl fumarate in cystic fibrosis bronchial epithelial cells","volume":"10","author":"Laselva","year":"2021","journal-title":"Cells"},{"key":"2025121505100581000_11.3.00970-2024.13","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/cells12131764","article-title":"Olive leaf extract (OLE) as a novel antioxidant that ameliorates the inflammatory response in cystic fibrosis","volume":"12","author":"Allegretta","year":"2023","journal-title":"Cells"},{"key":"2025121505100581000_11.3.00970-2024.14","doi-asserted-by":"crossref","first-page":"905468","DOI":"10.3389\/fmolb.2022.905468","article-title":"Insulin-like growth factor binding protein (IGFBP-6) as a novel regulator of inflammatory response in cystic fibrosis airway cells","volume":"9","author":"Laselva","year":"2022","journal-title":"Front Mol Biosci"},{"key":"2025121505100581000_11.3.00970-2024.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.03.013"},{"key":"2025121505100581000_11.3.00970-2024.16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063175"},{"key":"2025121505100581000_11.3.00970-2024.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.12.005"},{"key":"2025121505100581000_11.3.00970-2024.18","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201500166R"},{"key":"2025121505100581000_11.3.00970-2024.19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/jpm10020040","article-title":"The CFTR mutation c.3453G>C (D1152H) confers an anion selectivity defect in primary airway tissue that can be rescued by ivacaftor","volume":"10","author":"Laselva","year":"2020","journal-title":"J Pers Med"},{"key":"2025121505100581000_11.3.00970-2024.20","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1038\/s41467-021-26764-0","article-title":"Generation of functional ciliated cholangiocytes from human pluripotent stem cells","volume":"12","author":"Ogawa","year":"2021","journal-title":"Nat Commun"},{"key":"2025121505100581000_11.3.00970-2024.21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/jpm11040301","article-title":"Phenotyping rare CFTR mutations reveal functional expression defects restored by TRIKAFTA(TM)","volume":"11","author":"Laselva","year":"2021","journal-title":"J Pers Med"},{"key":"2025121505100581000_11.3.00970-2024.22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.stemcr.2021.09.020","article-title":"A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients","volume":"16","author":"Jiang","year":"2021","journal-title":"Stem Cell Rep"},{"key":"2025121505100581000_11.3.00970-2024.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2025121505100581000_11.3.00970-2024.24","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00198.2017"},{"key":"2025121505100581000_11.3.00970-2024.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.12.015"},{"key":"2025121505100581000_11.3.00970-2024.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36244-2"},{"key":"2025121505100581000_11.3.00970-2024.27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176379"},{"key":"2025121505100581000_11.3.00970-2024.28","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00519-24"},{"key":"2025121505100581000_11.3.00970-2024.29","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081174"},{"key":"2025121505100581000_11.3.00970-2024.30","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.3390\/cells10123419","article-title":"High-throughput functional analysis of CFTR and other apically localized proteins in iPSC-derived human intestinal organoids","volume":"10","author":"Xia","year":"2021","journal-title":"Cells"},{"key":"2025121505100581000_11.3.00970-2024.31","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"eLife"},{"key":"2025121505100581000_11.3.00970-2024.32","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219943"},{"key":"2025121505100581000_11.3.00970-2024.33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/ppul.26334","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment reduces airway inflammation in cystic fibrosis","volume":"58","author":"De Vuyst","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2025121505100581000_11.3.00970-2024.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202210-1938LE"},{"key":"2025121505100581000_11.3.00970-2024.35","doi-asserted-by":"crossref","first-page":"628722","DOI":"10.3389\/fphar.2021.628722","article-title":"Airway epithelial inflammation in vitro augments the rescue of mutant CFTR by current CFTR modulator therapies","volume":"12","author":"Gentzsch","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025121505100581000_11.3.00970-2024.36","doi-asserted-by":"crossref","first-page":"e150398","DOI":"10.1172\/JCI150398","article-title":"Inflammatory cytokines TNF-alpha and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators","volume":"131","author":"Rehman","year":"2021","journal-title":"J Clin Invest"},{"key":"2025121505100581000_11.3.00970-2024.37","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00746-2023"},{"key":"2025121505100581000_11.3.00970-2024.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2011.12.012"},{"key":"2025121505100581000_11.3.00970-2024.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071717"},{"key":"2025121505100581000_11.3.00970-2024.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003367"},{"key":"2025121505100581000_11.3.00970-2024.41","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1172\/JCI96273","article-title":"Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia","volume":"129","author":"Borcherding","year":"2019","journal-title":"J Clin Invest"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00970-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:10:17Z","timestamp":1765804217000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00970-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,27]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1183\/23120541.00970-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00970-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}